Vernon Williams, MD
Neurology · Los Angeles, CANPI 1437113313
Payments from drug & device makers
Across 79 payments — averaging $68.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pacira Pharmaceuticals Incorporated$3K
- Nevro Corp.$669
- AbbVie$520
- SPR Therapeutics, Inc$497
- Amgen$118
- Lilly USA, LLC$93
- plus $474 from 12 others
What the payments were for
- Consulting fees$2,69550%
- Travel & lodging$1202%
- Food & beverage$2,59548%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pacira Pharmaceuticals Incorporated | 7 | $3,040 |
| Nevro Corp. | 5 | $669 |
| AbbVie(2 entities) | 28 | $520 |
| SPR Therapeutics, Inc | 8 | $497 |
| Amgen(2 entities) | 5 | $118 |
| Lilly USA, LLC | 4 | $93 |
| Nalu Medical, Inc. | 4 | $85 |
| Assertio Therapeutics, Inc. | 4 | $78 |
| Innovation Technologies Inc | 1 | $63 |
| Biodelivery Sciences International, Inc. | 3 | $48 |
| Collegium Pharmaceutical, Inc. | 2 | $41 |
| Avanir Pharmaceuticals, Inc. | 2 | $35 |
| Vertex | 1 | $32 |
| Boston Scientific | 1 | $26 |
| Medtronic | 1 | $22 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| Neurometrix Inc | 1 | $14 |
| Pfizer | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Iovera$2,695
- Senza Spinal Cord Stimulation System$500
- SPRINT PNS System$385
- EXPAREL$244
- Omnia$143
How this compares
$5,409 in reported general payments places this provider in the 60th percentile of 1,996 neurology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MeloxicamMeloxicam, Submicronized | 12 | $7,828 |
| Diclofenac Sodium | 60 | $4,483 |
| Tizanidine Hcl | 82 | $909 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 25 | $688 |
| Gabapentin | 80 | $650 |
| Meloxicam | 133 | $458 |
| Celecoxib | 26 | $358 |
| Methylprednisolone | 46 | $310 |
| Duloxetine Hcl | 16 | $302 |
| Sumatriptan Succinate | 28 | $239 |
| Naproxen | 11 | $111 |
| Amitriptyline Hcl | 14 | $66 |
Paid to pharmacies, not to this prescriber.
Other neurology in Los Angeles
- Timothy CloughesyLos Angeles$33.1M
- Perry ShiehLos Angeles$8.2M
- Jeffrey SaverLos Angeles$2.9M
- David PiccioniLos Angeles$2.9M
- David LiebeskindLos Angeles$2.7M
- Michele TagliatiLos Angeles$2.5M
- Jennifer HuiLos Angeles$2.4M
- Susan PerlmanLos Angeles$2.2M
- Jeffrey CummingsLos Angeles$2M
- Bryan SpannLos Angeles$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.